At what pace is the diagnostic biomarkers market growing, and what is its estimated value?
The diagnostic biomarkers market size has grown rapidly in recent years. It will grow from $65.25 billion in 2024 to $75.67 billion in 2025 at a compound annual growth rate (CAGR) of 16.0%. The growth in the historic period can be attributed to the rising prevalence of chronic diseases, advancements in omics technologies, increasing demand for personalized medicine, growing awareness of early disease detection, and a surge in non-invasive diagnostic methods.
The diagnostic biomarkers market size is expected to see rapid growth in the next few years. It will grow to $136.57 billion in 2029 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to growing adoption of liquid biopsy techniques, increasing investment in biomarker research, rising focus on precision medicine, and expanding applications in neurodegenerative diseases. Major trends in the forecast period include the advancements in artificial intelligence and machine learning, the integration of multi-omics approaches, the development of point-of-care diagnostic tools, the shift towards digital biomarkers, the growing use of wearable health monitoring devices, and the increasing emphasis on biomarker validation and standardization.
Get Your Free Sample of The Global Diagnostic Biomarkers Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21171&type=smp
What are the top drivers to the rising demand in the diagnostic biomarkers market?
The growing prevalence of cancer drives the growth of the diagnostic biomarkers market going forward. The growing prevalence of cancer is driven by factors such as aging populations, lifestyle changes, environmental exposures, and improved diagnostic capabilities. Diagnostic biomarkers play a crucial role in cancer by enabling early detection, precise diagnosis, and personalized treatment strategies, improving patient outcomes. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 2,001,140 compared to 1,958,310 in 2023, reflecting a growth of 2.19%. The increasing prevalence of cancer is driving the growth of the diagnostic biomarkers market.
How is the diagnostic biomarkers market segmented?
The diagnostic biomarkers market covered in this report is segmented –
1) By Product: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers
2) By Application: Oncology, Metabolic Disease, Neurological Disease
3) By End User: Hospitals, Cancer Research Institutes, Diagnostic Labs
Subsegments:
1) By Safety Biomarkers: Toxicity Biomarkers, Organ-Specific Safety Biomarkers, Drug-Induced Injury Biomarkers
2) By Efficacy Biomarkers: Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers
3) By Validation Biomarkers: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/diagnostic-biomarkers-global-market-report
Who are the top competitors in the diagnostic biomarkers market?
Major companies operating in the diagnostic biomarkers market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, PerkinElmer Inc., Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Meso Scale Diagnostics LLC, EKF Diagnostics Holdings Plc, Sino Biological Inc., Enzo Biochem Inc., Biomarker Technologies Inc., Cisbio Bioassays, Signosis Inc., Epigenomics AG, LifeSign LLC, Banyan Biomarkers Inc., Biosims Technologies SAS
What significant trends should we anticipate in the diagnostic biomarkers market over the forecast period?
Major companies in the diagnostic biomarkers market are focused on developing non-invasive testing methods, such as blood-based biomarker tests, to enhance patient comfort and accessibility with personalized treatment strategies. A blood-based biomarker test refers to a diagnostic tool that analyzes specific biological markers in the blood to detect or monitor diseases, such as Alzheimer’s, in a minimally invasive manner. For instance, in July 2023, Quanterix Corporation, a US-based life sciences company, launched LucentAD, a blood-based biomarker test designed to assist healthcare providers in diagnosing Alzheimer’s disease (AD) in patients exhibiting early cognitive symptoms. The test measures plasma levels of phosphorylated tau protein at the 181 residue (p-Tau 181), a biomarker associated with amyloid pathology in the brain, a key indicator of AD. By providing a less invasive and more accessible diagnostic tool compared to traditional methods like cerebrospinal fluid analysis or amyloid positron emission tomography, LucentAD aims to streamline the evaluation process for suspected Alzheimer’s patients.
Which regional trends are influencing the diagnostic biomarkers market, and which area dominates the industry?
North America was the largest region in the diagnostic biomarkers market in 2024. The regions covered in the diagnostic biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Diagnostic Biomarkers Market Report 2025 Offer?
The diagnostic biomarkers market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A diagnostic biomarker is a biological measure that assists in the diagnosis of a disease, helping to differentiate it from other conditions. It can encompass various findings, including laboratory results, radiological images, genetic markers, and physiological changes, and may also provide insights into disease progression and treatment efficacy.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21171
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
